Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane

H J Krämer1, J Stevens, F Grimminger

  • 1Department of Internal Medicine, Justus-Liebig University, Giessen, Germany.

Biochemical Pharmacology
|October 25, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Update pulmonary arterial hypertension : Definitions, diagnosis, therapy].

Der Internist·2017
Same author

[Medical treatment of pulmonary hypertension: what's new?].

Der Internist·2015
Same author

Combined suppression of the intrarenal and circulating vasoconstrictor renin-ACE-ANG II axis and augmentation of the vasodilator ACE2-ANG 1-7-Mas axis attenuates the systemic hypertension in Ren-2 transgenic rats exposed to chronic hypoxia.

Physiological research·2014
Same author

Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.

Oncogene·2012
Same author

Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy.

European respiratory review : an official journal of the European Respiratory Society·2010
Same author

Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats.

The European respiratory journal·2010
Same journal

Methylated SNHG3 lncRNA counteracts PSMD4-inhibited angiogenesis by HnRNPA2B1 SUMOylation in peripheral arterial disease.

Biochemical pharmacology·2026
Same journal

The organelle-targeting duality of nanomaterials: physicochemical property-guided therapeutic effects and toxicological outcomes.

Biochemical pharmacology·2026
Same journal

The central role of endoplasmic reticulum stress in Parkinson's disease and targeted therapeutic strategies.

Biochemical pharmacology·2026
Same journal

Mechanisms involved in the regulation of carbohydrate and lipid metabolism by oleanane-type pentacyclic triterpenes.

Biochemical pharmacology·2026
Same journal

Myricitrin alleviates paraquat-induced acute lung injury via PERK pathway to attenuate endoplasmic reticulum stress and mitochondrial dysfunction.

Biochemical pharmacology·2026
Same journal

Design, synthesis, and biological evaluation of Combretastatin A4 dimers for the treatment of hepatocellular carcinoma.

Biochemical pharmacology·2026
See all related articles

Dietary n-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DCHA), suppress platelet thromboxane A2 (TxA2) generation. EPA and DCHA act as competitive inhibitors, offering a potential therapeutic strategy to reduce inflammatory and coagulatory events.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Nutrition Science

Background:

  • Dietary n-3 fatty acids, particularly from fish oil, are investigated for their anti-inflammatory and anti-coagulatory properties.
  • Parenteral nutrition enriched with n-3 fatty acids increases plasma concentrations of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DCHA).

Purpose of the Study:

  • To investigate the effect of free EPA and DCHA on platelet thromboxane A2 (TxA2) and thromboxane A3 (TxA3) formation.
  • To determine if EPA and DCHA can suppress TxA2 generation and platelet aggregation.

Main Methods:

  • Quantification of stable hydrolysis products of thromboxanes (TxB2 and TxB3) using high-performance liquid chromatography-ELISA.
  • Incubation of washed human platelets with arachidonic acid (AA), A23187, or thrombin, with or without varying concentrations of EPA or DCHA.

Related Experiment Videos

  • Measurement of platelet aggregation induced by U46619.

    • Main Results:

    • EPA and DCHA significantly suppressed platelet TxA2 generation in a dose-dependent manner, acting as competitive inhibitors.
    • EPA was a poor substrate for cyclooxygenase/thromboxane synthase, leading to some TxA3 formation, while DCHA was not a substrate.
    • Both EPA and DCHA dose-dependently inhibited U46619-provoked platelet aggregation.

    Conclusions:

    • EPA and DCHA are potent inhibitors of TxA2 generation in platelets.
    • Enrichment of plasma free fatty acids with n-3 lipids may be a therapeutic approach to mitigate pro-aggregatory and vasoconstrictory effects of TxA2.